Search PubMed⌕ Search

Biomedical subjects

S Hafiz

Publications and source records attributed to S Hafiz.

100 records · Page 6Linked to original sources
PubMed1976

Prolonged survival of Neisseria gonorrhoeae in a new liquid medium.

Despite substantial improvements in solid culture media for gonococci and the development of liquid media for the short-term growth of the organism, we know of no study of the long-term survival of Neisseria gonorrhoeae in liquid medium. A new liquid medium for N. gonorrhoeae formulated in this laboratory is simple, efficient, and promising. It will support growth and sustain inoculated colony types for periods of up to 3 weeks. Moreover, it has been used successfully for the primary isolation of gonococci from patients. From the evidence at present available, we believe that this medium will find a useful place in gonococcal research.

Culture Media↗
PubMed1975

Clostridium defficiel in the urogenital tract of males and females.

A study of the occurrence of Clostridium difficile in the urogenital tract of males and females revealed higher isolation-rates in patients attending the special (venereal-disease) clinic than in patients attending family-planning and urological clinics. The presence of Cl. difficile in patients with venereal diseases is being investigated to see if the organism is simply an opportunist infecting a urethra disturbed by some antecedent disease, or if it is perhaps a primary cuase of disease.

Adult↗
PubMedDate not supplied

Efficacy of albendazole in giardiasis.

Albendazole and metronidazole were compared in 68 patients diagnosed positive for giardiasis. Albendazole 1200 mg, one dose was given to 24 patients, albendazole 400 mg twice a day for 3 days was given to 23 patients, and metronidazole 400 mg 3 times a day for 5 days to 21 patients. Response to therapy was monitored by clinical examination and analysis of fresh faecal samples on days 0, 3, 7 and 10. Response to the single dose of albendazole was 55%, to the divided dose of albendazole 70%, and to metronidazole 84%. The results show that albendazole, originally recommended for helminthic infection, can also be used in patients with mixed protozoal infection or for infections resistant to metronidazole.

Abdominal Pain↗
PubMedDate not supplied

Respiratory symptoms due to Branhamella catarrhalis and other Neisseria species infections--response to erythromycin therapy.

Neisseria microorganisms (Neisseria lactamica, Neisseria sicca, and Neisseria mucosa) are regarded as normal respiratory commensals. Branhamella catarrhalis (formerly Neisseria catarrhalis) has also been regarded as a normal respiratory commensal, but reports indicate that it can be pathogenic. The role of Neisseria spp was studied in 160 patients with chest infections and symptoms and signs of obstructive respiratory disease. Group I patients (n = 140) had a history of asthma, bronchitis, and emphysema. Group II patients (n = 20) had an initially responsive pulmonary tuberculosis but presented with fever and obstructive airway disease. Group I patients had disease that was difficult to control despite increased bronchodilator therapy, but they responded dramatically after two to three days of appropriate antibiotic therapy. Patients in group II showed a similar response to erythromycin. Neisseria infection was responsible for precipitating or exacerbating respiratory distress in both groups. Accordingly, it is concluded that Neisseria can be pathogenic and that patients with fever and obstructive respiratory symptoms require treatment.

Adolescent↗
PubMedDate not supplied

Enoxacin: in vitro efficacy and its future therapeutic role in the Pakistani health-care system.

Because laboratory microbiological diagnosis is not readily available for 80% of the total population of Pakistan (120 million people), clinicians in large rural areas have been compelled to use several antibiotics in any individual case of resistant and severe infection. This practice has resulted in an increasing number of resistant strains, particularly those of Salmonella, Pseudomonas, Escherichia coli, Klebsiella, Enterobacter, Staphylococcus, and Shigella. Also, multiple resistance to penicillin, ampicillin, carbenicillin, cotrimoxazole, chloramphenicol, fosfomycin, gentamicin, nalidixic acid, vancomycin, amoxicillin, cefotaxime, and cloxacillin has been recognized. In view of this limitation in antimicrobial therapy, enoxacin, a second-generation quinolone, has been assessed in vitro against resistant and other organisms, and its breakpoint sensitivity has been compared with another quinolone, ofloxacin. The findings indicate that new quinolones such as enoxacin may prove to be helpful in the treatment of individuals suffering from severe and resistant bacterial infections for which no microbiologic diagnosis is available.

Bacterial Infections↗